In vivo CAR (Chimeric Antigen Receptor) therapies are poised to revolutionize immunotherapy by moving beyond the limitations of traditional ex vivo approaches. These therapies involve programming immune cells directly within the body to target and eliminate diseases. This panel session brings together experts from leading companies to explore why in vivo CARs are the future of immunotherapy. This collaborative session will explore emerging data and the innovative technologies that underpin this next-generation modality. Attendees are invited to join this panel for a unique opportunity to gain valuable insights from industry pioneers, engage in interactive discussions, and learn about the groundbreaking immunotherapies poised to transform patient outcomes.